Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study
Paulien Van Loocke(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Jeroen Meulemans(KU Leuven), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Esther Hauben(Universitair Ziekenhuis Leuven), Vincent Vander Poorten(KU Leuven), Sandra Nuyts(Cancer Institute (WIA)), Abhishek D. Garg(KU Leuven), Robin Willaert(KU Leuven), Robert Hermans(Universitair Ziekenhuis Leuven), Davide Di Santo(KU Leuven), Oliver Bechter(Universitair Ziekenhuis Leuven)
Cited by 3
Related Papers
EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research
|Nature Methods|2017|1.3k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
|The EMBO Journal|2012|772
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573